{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T18:34:31Z","timestamp":1789583671615,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T00:00:00Z","timestamp":1723420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T00:00:00Z","timestamp":1723420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"DOI":"10.1007\/s10741-024-10428-4","type":"journal-article","created":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T23:02:22Z","timestamp":1723503742000},"page":"1175-1185","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacological management of heart failure in adults with congenital heart disease"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-8001-6414","authenticated-orcid":false,"given":"Barbara","family":"Karnkowska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wissam","family":"Harmouch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Newman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bisma","family":"Khwaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Faluk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Chatila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,12]]},"reference":[{"key":"10428_CR1","unstructured":"CDC. Data and statistics on congenital heart defects | CDC. Centers for Disease Control and Prevention. Published September 19, 2023. Accessed October 6, 2023. https:\/\/www.cdc.gov\/ncbddd\/heartdefects\/data.html"},{"key":"10428_CR2","unstructured":"Congenital disorders. Accessed October 6, 2023. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/birth-defects"},{"issue":"2","key":"10428_CR3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1161\/CIRCULATIONAHA.115.019307","volume":"134","author":"SM Gilboa","year":"2016","unstructured":"Gilboa SM, Devine OJ, Kucik JE et al (2016) Congenital heart defects in the United States: estimating the magnitude of the affected population in 2010. Circulation 134(2):101\u2013109. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.019307","journal-title":"Circulation"},{"issue":"9","key":"10428_CR4","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1161\/CIRCULATIONAHA.113.008396","volume":"130","author":"AJ Marelli","year":"2014","unstructured":"Marelli AJ, Ionescu-Ittu R, Mackie AS, Guo L, Dendukuri N, Kaouache M (2014) Lifetime prevalence of congenital heart disease in the general population from 2000 to 2010. Circulation 130(9):749\u2013756. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.008396","journal-title":"Circulation"},{"issue":"22","key":"10428_CR5","doi-asserted-by":"publisher","first-page":"e017704","DOI":"10.1161\/JAHA.120.017704","volume":"9","author":"Z Mandalenakis","year":"2020","unstructured":"Mandalenakis Z, Giang KW, Eriksson P et al (2020) Survival in children with congenital heart disease: have we reached a peak at 97%? J Am Heart Assoc Cardiovasc Cerebrovasc Dis 9(22):e017704. https:\/\/doi.org\/10.1161\/JAHA.120.017704","journal-title":"J Am Heart Assoc Cardiovasc Cerebrovasc Dis"},{"issue":"4","key":"10428_CR6","doi-asserted-by":"publisher","first-page":"e007907","DOI":"10.1161\/JAHA.117.007907","volume":"7","author":"M Wu","year":"2018","unstructured":"Wu M, Lu C, Chen H, Kao F, Huang S (2018) Adult congenital heart disease in a nationwide population 2000\u20132014: epidemiological trends, arrhythmia, and standardized mortality ratio. J Am Heart Assoc 7(4):e007907. https:\/\/doi.org\/10.1161\/JAHA.117.007907","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"10428_CR7","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1093\/eurheartj\/eht257","volume":"35","author":"O Tutarel","year":"2014","unstructured":"Tutarel O, Kempny A, Alonso-Gonzalez R et al (2014) Congenital heart disease beyond the age of 60: emergence of a new population with high resource utilization, high morbidity, and high mortality. Eur Heart J 35(11):725\u2013732. https:\/\/doi.org\/10.1093\/eurheartj\/eht257","journal-title":"Eur Heart J"},{"issue":"12","key":"10428_CR8","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1161\/CIRCULATIONAHA.122.060834","volume":"147","author":"M Dellborg","year":"2023","unstructured":"Dellborg M, Giang KW, Eriksson P et al (2023) Adults with congenital heart disease: trends in event-free survival past middle age. Circulation 147(12):930\u2013938. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.060834","journal-title":"Circulation"},{"issue":"2","key":"10428_CR9","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jacc.2020.05.025","volume":"76","author":"M Gurvitz","year":"2020","unstructured":"Gurvitz M, Dunn JE, Bhatt A et al (2020) Characteristics of adults with congenital heart defects in the United States. J Am Coll Cardiol 76(2):175\u2013182. https:\/\/doi.org\/10.1016\/j.jacc.2020.05.025","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10428_CR10","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1161\/CIRCULATIONAHA.122.061546","volume":"147","author":"N Bergh","year":"2023","unstructured":"Bergh N, Skoglund K, Fedchenko M et al (2023) Risk of heart failure in congenital heart disease: a nationwide register-based cohort study. Circulation 147(12):982\u2013984. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.061546","journal-title":"Circulation"},{"issue":"9","key":"10428_CR11","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1161\/CIRCULATIONAHA.117.029590","volume":"137","author":"Z Mandalenakis","year":"2018","unstructured":"Mandalenakis Z, Rosengren A, Lappas G et al (2018) Atrial fibrillation burden in young patients with congenital heart disease. Circulation 137(9):928\u2013937. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.029590","journal-title":"Circulation"},{"issue":"26","key":"10428_CR12","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1093\/eurheartj\/ehaa874","volume":"42","author":"M Fedchenko","year":"2020","unstructured":"Fedchenko M, Mandalenakis Z, Giang KW, Rosengren A, Eriksson P, Dellborg M (2020) Long-term outcomes after myocardial infarction in middle-aged and older patients with congenital heart disease\u2014a nationwide study. Eur Heart J 42(26):2577\u20132586. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa874","journal-title":"Eur Heart J"},{"issue":"10","key":"10428_CR13","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1136\/heartjnl-2020-318246","volume":"107","author":"DS Burstein","year":"2021","unstructured":"Burstein DS, Rossano JW, Griffis H et al (2021) Greater admissions, mortality and cost of heart failure in adults with congenital heart disease. Heart 107(10):807\u2013813. https:\/\/doi.org\/10.1136\/heartjnl-2020-318246","journal-title":"Heart"},{"issue":"3","key":"10428_CR14","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1016\/j.ijcard.2013.03.003","volume":"168","author":"AC Zomer","year":"2013","unstructured":"Zomer AC, Vaartjes I, van der Velde ET et al (2013) Heart failure admissions in adults with congenital heart disease; risk factors and prognosis. Int J Cardiol 168(3):2487\u20132493. https:\/\/doi.org\/10.1016\/j.ijcard.2013.03.003","journal-title":"Int J Cardiol"},{"key":"10428_CR15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ijcard.2016.02.133","volume":"211","author":"CC Engelings","year":"2016","unstructured":"Engelings CC, Helm PC, Abdul-Khaliq H et al (2016) Cause of death in adults with congenital heart disease - an analysis of the German National Register for Congenital Heart Defects. Int J Cardiol 211:31\u201336. https:\/\/doi.org\/10.1016\/j.ijcard.2016.02.133","journal-title":"Int J Cardiol"},{"issue":"10","key":"10428_CR16","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1093\/eurheartj\/ehq032","volume":"31","author":"CL Verheugt","year":"2010","unstructured":"Verheugt CL, Uiterwaal CSPM, van der Velde ET et al (2010) Mortality in adult congenital heart disease. Eur Heart J 31(10):1220\u20131229. https:\/\/doi.org\/10.1093\/eurheartj\/ehq032","journal-title":"Eur Heart J"},{"issue":"2","key":"10428_CR17","doi-asserted-by":"publisher","first-page":"529","DOI":"10.21037\/cdt-20-632","volume":"11","author":"E Zengin","year":"2021","unstructured":"Zengin E, Sinning C, Blaum C et al (2021) Heart failure in adults with congenital heart disease: a narrative review. Cardiovasc Diagn Ther 11(2):529\u2013537. https:\/\/doi.org\/10.21037\/cdt-20-632","journal-title":"Cardiovasc Diagn Ther"},{"issue":"22","key":"10428_CR18","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1161\/CIRCULATIONAHA.115.017202","volume":"132","author":"GP Diller","year":"2015","unstructured":"Diller GP, Kempny A, Alonso-Gonzalez R et al (2015) Survival prospects and circumstances of death in contemporary adult congenital heart disease patients under follow-up at a large tertiary centre. Circulation 132(22):2118\u20132125. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.017202","journal-title":"Circulation"},{"issue":"4","key":"10428_CR19","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.hfc.2018.06.005","volume":"14","author":"A Sabanayagam","year":"2018","unstructured":"Sabanayagam A, Cavus O, Williams J, Bradley E (2018) Management of heart failure in adult congenital heart disease. Heart Fail Clin 14(4):569\u2013577. https:\/\/doi.org\/10.1016\/j.hfc.2018.06.005","journal-title":"Heart Fail Clin"},{"issue":"5","key":"10428_CR20","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1161\/01.cir.96.5.1507","volume":"96","author":"AA Kouatli","year":"1997","unstructured":"Kouatli AA, Garcia JA, Zellers TM, Weinstein EM, Mahony L (1997) Enalapril does not enhance exercise capacity in patients after Fontan procedure. Circulation 96(5):1507\u20131512. https:\/\/doi.org\/10.1161\/01.cir.96.5.1507","journal-title":"Circulation"},{"issue":"5","key":"10428_CR21","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/s0002-9149(00)01452-1","volume":"87","author":"SJ Hechter","year":"2001","unstructured":"Hechter SJ, Fredriksen PM, Liu P, Veldtman G, Merchant N, Freeman M, Therrien J, Benson L, Siu S, Webb G (2001) Angiotensin-converting enzyme inhibitors in adults after the Mustard procedure. Am J Cardiol 87(5):660\u20133, A11. https:\/\/doi.org\/10.1016\/s0002-9149(00)01452-1","journal-title":"Am J Cardiol"},{"issue":"11","key":"10428_CR22","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1016\/s0002-9149(01)02098-7","volume":"88","author":"SJ Lester","year":"2001","unstructured":"Lester SJ, McElhinney DB, Viloria E, Reddy GP, Ryan E, Tworetzky W, Schiller NB, Foster E (2001) Effects of losartan in patients with a systemically functioning morphologic right ventricle after atrial repair of transposition of the great arteries. Am J Cardiol 88(11):1314\u20131316. https:\/\/doi.org\/10.1016\/s0002-9149(01)02098-7","journal-title":"Am J Cardiol"},{"issue":"12","key":"10428_CR23","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.jacc.2018.08.1030","volume":"73","author":"E Zaragoza-Macias","year":"2019","unstructured":"Zaragoza-Macias E, Zaidi AN, Dendukuri N, Marelli A (2019) Medical therapy for systemic right ventricles: a systematic review (Part 1) for the 2018 AHA\/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 73(12):1564\u20131578. https:\/\/doi.org\/10.1016\/j.jacc.2018.08.1030","journal-title":"J Am Coll Cardiol"},{"key":"10428_CR24","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.amjcard.2006.10.025","volume":"99","author":"ARK Doughan","year":"2007","unstructured":"Doughan ARK, McConnell ME, Book WM (2007) Effect of beta blockers (carvedilol or metoprolol XL) in patients with transposition of great arteries and dysfunction of the systemic right ventricle. Am J Cardiol 99:704\u2013706","journal-title":"Am J Cardiol"},{"issue":"6","key":"10428_CR25","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1017\/S1047951110000764","volume":"20","author":"R Bouallal","year":"2010","unstructured":"Bouallal R, Godart F, Francart C, Richard A, Foucher-Hossein C, Lions C (2010) Interest of \u03b2-blockers in patients with right ventricular systemic dysfunction. Cardiol Young 20(6):615\u2013619. https:\/\/doi.org\/10.1017\/S1047951110000764","journal-title":"Cardiol Young"},{"issue":"9","key":"10428_CR26","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/s0828-282x(06)70293-8","volume":"22","author":"CB Josephson","year":"2006","unstructured":"Josephson CB, Howlett JG, Jackson SD, Finley J, Kells CM (2006) A case series of systemic right ventricular dysfunction post atrial switch for simple D-transposition of the great arteries: the impact of beta-blockade. Can J Cardiol 22(9):769\u2013772. https:\/\/doi.org\/10.1016\/s0828-282x(06)70293-8","journal-title":"Can J Cardiol"},{"issue":"2","key":"10428_CR27","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ijcard.2006.01.048","volume":"114","author":"A Giardini","year":"2007","unstructured":"Giardini A, Lovato L, Donti A, Formigari R, Gargiulo G, Picchio FM, Fattori R (2007) A pilot study on the effects of carvedilol on right ventricular remodelling and exercise tolerance in patients with systemic right ventricle. Int J Cardiol 114(2):241\u2013246. https:\/\/doi.org\/10.1016\/j.ijcard.2006.01.048","journal-title":"Int J Cardiol"},{"key":"10428_CR28","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ijcard.2019.06.031","volume":"300","author":"SJ Maurer","year":"2020","unstructured":"Maurer SJ, Pujol Salvador C, Schiele S, Hager A, Ewert P, Tutarel O (2020) Sacubitril\/valsartan for heart failure in adults with complex congenital heart disease. Int J Cardiol 300:137\u2013140. https:\/\/doi.org\/10.1016\/j.ijcard.2019.06.031","journal-title":"Int J Cardiol"},{"key":"10428_CR29","doi-asserted-by":"publisher","first-page":"100268","DOI":"10.1016\/j.ijcchd.2021.100268","volume":"6","author":"L Yan","year":"2021","unstructured":"Yan L, Loh JK, Le Tan J (2021) Sacubitril\/valsartan for heart failure in patients with complex adult congenital heart disease \u2013 Experience from a tertiary centre in Singapore. International Journal of Cardiology Congenital Heart Disease 6:100268. https:\/\/doi.org\/10.1016\/j.ijcchd.2021.100268","journal-title":"International Journal of Cardiology Congenital Heart Disease"},{"issue":"21","key":"10428_CR30","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1136\/heartjnl-2020-318074","volume":"107","author":"TE Zandstra","year":"2021","unstructured":"Zandstra TE, Nederend M, Jongbloed MRM et al (2021) Sacubitril\/valsartan in the treatment of systemic right ventricular failure. Heart 107(21):1725\u20131730. https:\/\/doi.org\/10.1136\/heartjnl-2020-318074","journal-title":"Heart"},{"issue":"2","key":"10428_CR31","doi-asserted-by":"publisher","first-page":"e009848","DOI":"10.1161\/CIRCHEARTFAILURE.122.009848","volume":"16","author":"F Fusco","year":"2023","unstructured":"Fusco F, Scognamiglio G, Merola A et al (2023) Safety and efficacy of sacubitril\/valsartan in patients with a failing systemic right ventricle: a prospective single-center study. Circ Heart Fail 16(2):e009848. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.122.009848","journal-title":"Circ Heart Fail"},{"issue":"3","key":"10428_CR32","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1002\/ehf2.13871","volume":"9","author":"AD Egorova","year":"2022","unstructured":"Egorova AD, Nederend M, Tops LF, Vliegen HW, Jongbloed MRM, Ki\u00e8s P (2022) The first experience with sodium-glucose cotransporter 2 inhibitor for the treatment of systemic right ventricular failure. ESC Heart Fail 9(3):2007\u20132012. https:\/\/doi.org\/10.1002\/ehf2.13871","journal-title":"ESC Heart Fail"},{"key":"10428_CR33","doi-asserted-by":"publisher","first-page":"5243594","DOI":"10.1155\/2022\/5243594","volume":"2022","author":"J Muneuchi","year":"2022","unstructured":"Muneuchi J, Sugitani Y, Kobayashi M, Ezaki H, Yamada H, Watanabe M (2022) Feasibility and safety of sodium glucose cotransporter-2 inhibitors in adults with heart failure after the fontan procedure. Case Rep Cardiol 2022:5243594. https:\/\/doi.org\/10.1155\/2022\/5243594. (Published 2022 Dec 9)","journal-title":"Case Rep Cardiol"},{"issue":"6","key":"10428_CR34","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.cardfail.2023.03.011","volume":"29","author":"J Saef","year":"2023","unstructured":"Saef J, Sundaravel S, Ortega-Legaspi J, Vaikunth S (2023) Safety and treatment experience with sodium\/glucose cotransporter-2 inhibitors in adult patients with congenital heart disease. J Card Fail 29(6):974\u2013975. https:\/\/doi.org\/10.1016\/j.cardfail.2023.03.011","journal-title":"J Card Fail"},{"key":"10428_CR35","doi-asserted-by":"publisher","first-page":"1093201","DOI":"10.3389\/fcvm.2023.1093201","volume":"10","author":"RML Neijenhuis","year":"2023","unstructured":"Neijenhuis RML, Nederend M, Jongbloed MRM et al (2023) The potential of sodium-glucose cotransporter 2 inhibitors for the treatment of systemic right ventricular failure in adults with congenital heart disease. Front Cardiovasc Med 10:1093201. https:\/\/doi.org\/10.3389\/fcvm.2023.1093201. (Published 2023 Jun 26)","journal-title":"Front Cardiovasc Med"},{"issue":"14","key":"10428_CR36","doi-asserted-by":"publisher","first-page":"e698","DOI":"10.1161\/CIR.0000000000000603","volume":"139","author":"KK Stout","year":"2019","unstructured":"Stout KK, Daniels CJ, Aboulhosn JA, Bozkurt B, Broberg CS, Colman JM, Crumb SR, Dearani JA, Fuller S, Gurvitz M, Khairy P, Landzberg MJ, Saidi A, Valente AM, Van Hare GF (2019) 2018 AHA\/ACC Guideline for the management of adults with congenital heart disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 139(14):e698\u2013e800. https:\/\/doi.org\/10.1161\/CIR.0000000000000603. (Erratum.In:Circulation.2019Apr2;139(14):e833-e834)","journal-title":"Circulation"},{"issue":"6","key":"10428_CR37","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1093\/eurheartj\/ehaa554","volume":"42","author":"H Baumgartner","year":"2021","unstructured":"Baumgartner H, De Backer J, Babu-Narayan SV, Budts W, Chessa M, Diller GP, Lung B, Kluin J, Lang IM, Meijboom F, Moons P, Mulder BJM, Oechslin E, Roos-Hesselink JW, Schwerzmann M, Sondergaard L, Zeppenfeld K (2021) ESC Scientific Document Group. 2020 ESC Guidelines for the management of adult congenital heart disease. Eur Heart J 42(6):563\u2013645. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa554","journal-title":"Eur Heart J"},{"issue":"9","key":"10428_CR38","doi-asserted-by":"publisher","first-page":"892861","DOI":"10.3389\/fcvm.2022.892861","volume":"26","author":"D Iacobazzi","year":"2022","unstructured":"Iacobazzi D, Alvino VV, Caputo M, Madeddu P (2022) Accelerated cardiac aging in patients with congenital heart disease. Front Cardiovasc Med 26(9):892861. https:\/\/doi.org\/10.3389\/fcvm.2022.892861. (Erratum.In:FrontCardiovascMed.2022Dec15;9:1112510)","journal-title":"Front Cardiovasc Med"},{"issue":"23","key":"10428_CR39","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","volume":"316","author":"CONSENSUS Trial Study Group","year":"1987","unstructured":"CONSENSUS Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316(23):1429\u201335. https:\/\/doi.org\/10.1056\/NEJM198706043162301","journal-title":"N Engl J Med"},{"issue":"5","key":"10428_CR40","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1056\/NEJM199108013250501","volume":"325","author":"S Yusuf","year":"1991","unstructured":"Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325(5):293\u2013302. https:\/\/doi.org\/10.1056\/NEJM199108013250501","journal-title":"N Engl J Med"},{"issue":"4","key":"10428_CR41","doi-asserted-by":"publisher","first-page":"e190027","DOI":"10.1148\/ryct.2019190027","volume":"1","author":"NB Spath","year":"2019","unstructured":"Spath NB, Gomez M, Everett RJ, Semple S, Chin CWL, White AC, Japp AG, Newby DE, Dweck MR (2019) Global longitudinal strain analysis using cardiac MRI in aortic stenosis: comparison with left ventricular remodeling, myocardial fibrosis, and 2-year clinical outcomes. Radiol Cardiothorac Imaging 1(4):e190027. https:\/\/doi.org\/10.1148\/ryct.2019190027","journal-title":"Radiol Cardiothorac Imaging"},{"issue":"15","key":"10428_CR42","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.3390\/diagnostics13152470","volume":"13","author":"A\u00c1 Moln\u00e1r","year":"2023","unstructured":"Moln\u00e1r A\u00c1, S\u00e1nta A, Merkely B (2023) Echocardiography imaging of the right ventricle: focus on three-dimensional echocardiography. Diagnostics 13(15):2470. https:\/\/doi.org\/10.3390\/diagnostics13152470","journal-title":"Diagnostics"},{"issue":"15","key":"10428_CR43","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, B\u00f6hm M, Choi DJ, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-La Rocca HP, Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde MF, Spinar J, Squire I, Taddei S, Wanner C, Zannad F, EMPEROR-Reduced Trial Investigators (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383(15):1413\u20131424. https:\/\/doi.org\/10.1056\/NEJMoa2022190","journal-title":"N Engl J Med"},{"issue":"6","key":"10428_CR44","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.ijcard.2013.10.014","volume":"169","author":"M Westhoff-Bleck","year":"2013","unstructured":"Westhoff-Bleck M, Podewski E, Tutarel O, Wenzel D, CappelloCBertram H et al (2013) Prognostic value of NT-proBNP in patients with systemic morphological right ventricles: a single-centre experience. Int J Cardiol 169(6):433\u20138. https:\/\/doi.org\/10.1016\/j.ijcard.2013.10.014","journal-title":"Int J Cardiol"},{"issue":"21","key":"10428_CR45","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, B\u011blohl\u00e1vek J, B\u00f6hm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Duk\u00e1t A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O\u2019Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sj\u00f6strand M, Langkilde AM, DAPA-HF Trial Committees and Investigators (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381(21):1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-024-10428-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-024-10428-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-024-10428-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T08:21:05Z","timestamp":1728116465000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-024-10428-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,12]]},"references-count":45,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["10428"],"URL":"https:\/\/doi.org\/10.1007\/s10741-024-10428-4","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,12]]},"assertion":[{"value":"25 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}